Literature DB >> 22574621

Determinants of epidermal nerve fibre density in antiretroviral-naïve HIV-infected individuals.

Cm Shikuma1, M Gerschenson, J Ananworanich, Vg Valcour, N Teeratakulpisarn, T Jadwattanakul, V Degruttola, C-Y Liang, Jc McArthur, Gj Ebenezer, N Chomchey, P Praihirunkit, P Hongchookiath, P Mathajittiphun, B Nakamoto, P Hauer, P Phanuphak, N Phanuphak.   

Abstract

OBJECTIVES: Distal leg epidermal nerve fibre density (ENFD) is a validated predictor of small unmyelinated nerve fibre damage and neuropathy risk in HIV infection. As pre-existing damage may increase the risk of neuropathy following antiretroviral (ARV) therapy, particularly when the regimen contains stavudine (d4T), we assessed the relationship between ENFD and various parameters including mitochondrial factors in HIV-infected Thai individuals naïve to ARV therapy.
METHODS: Distal leg and proximal thigh ENFDs were quantified in HIV-infected Thai individuals without neuropathy prior to randomization to a HIV clinical trial that focused on mitochondrial toxicity issues. We assessed their association with various clinical and immunovirological parameters as well as with peripheral blood mononuclear cell (PBMC) mitochondrial (mt) DNA copies/cell, oxidative phosphorylation (OXPHOS) complex I (CI) and complex IV (CIV) enzyme activities, and mt 8-oxo-deoxyguanine (8-oxo-dG) break frequencies.
RESULTS: In 132 subjects, the median (interquartile range) ENFD (fibres/mm) values were 21.0 (16.2-26.6) for the distal leg and 31.7 (26.2-40.0) for the proximal thigh. By linear regression, lower CD4 count (P < 0.01), older age (P < 0.01), increased body mass index (BMI) (P = 0.04), increased height (P = 0.02), and higher PBMC OXPHOS activity as measured by CIV activity (P = 0.02) were associated with lower distal leg ENFD.
CONCLUSIONS: Older age, increased height, higher BMI, poorer immunological status and higher PBMC OXPHOS activity are associated with lower distal leg ENFD in HIV-infected subjects free of neuropathy prior to initiation of first-time ARV therapy.
© 2012 British HIV Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22574621      PMCID: PMC3654839          DOI: 10.1111/j.1468-1293.2012.01024.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  23 in total

Review 1.  HIV-associated sensory neuropathies.

Authors:  Sanjay C Keswani; Carlos A Pardo; Catherine L Cherry; Ahmet Hoke; Justin C McArthur
Journal:  AIDS       Date:  2002-11-08       Impact factor: 4.177

2.  Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort.

Authors:  Kenneth A Lichtenstein; Carl Armon; Anna Baron; Anne C Moorman; Kathleen C Wood; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2004-12-06       Impact factor: 9.079

3.  Human immunodeficiency virus and the peripheral nervous system workshop.

Authors:  F J Brinley; C A Pardo; A Verma
Journal:  Arch Neurol       Date:  2001-10

4.  Short communication: transplacental nucleoside analogue exposure and mitochondrial parameters in HIV-uninfected children.

Authors:  Susan B Brogly; Salvatore DiMauro; Russell B Van Dyke; Paige L Williams; Ali Naini; Daniel E Libutti; Julia Choi; Michelle Chung; Mariana Gerschenson
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-15       Impact factor: 2.205

5.  Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey.

Authors:  Y T So; D M Holtzman; D I Abrams; R K Olney
Journal:  Arch Neurol       Date:  1988-09

6.  Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

Authors:  Hélène C F Côté; Zabrina L Brumme; Kevin J P Craib; Christopher S Alexander; Brian Wynhoven; Lillian Ting; Hubert Wong; Marianne Harris; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Journal:  N Engl J Med       Date:  2002-03-14       Impact factor: 91.245

7.  Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy.

Authors:  E A Childs; R H Lyles; O A Selnes; B Chen; E N Miller; B A Cohen; J T Becker; J Mellors; J C McArthur
Journal:  Neurology       Date:  1999-02       Impact factor: 9.910

8.  Symptomatic distal sensory polyneuropathy in HIV after age 50.

Authors:  M R Watters; P W Poff; B T Shiramizu; P S Holck; K M S Fast; C M Shikuma; V G Valcour
Journal:  Neurology       Date:  2004-04-27       Impact factor: 9.910

9.  Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals.

Authors:  Oscar Miró; Sònia López; Esteban Martínez; Enric Pedrol; Ana Milinkovic; Elisabeth Deig; Glòria Garrabou; Jordi Casademont; Josep M Gatell; Francesc Cardellach
Journal:  Clin Infect Dis       Date:  2004-08-13       Impact factor: 9.079

10.  HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank.

Authors:  Susan Morgello; Lydia Estanislao; David Simpson; Anthony Geraci; Alessandro DiRocco; Pieter Gerits; Elizabeth Ryan; Tatiana Yakoushina; Shafat Khan; Rashid Mahboob; Mubasher Naseer; David Dorfman; Victoria Sharp
Journal:  Arch Neurol       Date:  2004-04
View more
  6 in total

1.  Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy.

Authors:  Todd Hulgan; Rebecca T Levinson; Mariana Gerschenson; Nittaya Phanuphak; Jintanat Ananworanich; Nipat Teeratakulpisarm; Tanate Jadwattanakul; Daniel E LiButti; Heidi Fink; Justin C McArthur; Gigi J Ebenezer; Peter Hauer; Deborah Murdock; Cecilia M Shikuma; David C Samuels
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

Review 2.  Uses of skin biopsy for sensory and autonomic nerve assessment.

Authors:  M Iliza Myers; Amanda C Peltier
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

3.  Distal leg epidermal nerve fiber density as a surrogate marker of HIV-associated sensory neuropathy risk: risk factors and change following initial antiretroviral therapy.

Authors:  Cecilia M Shikuma; Kara Bennett; Jintanat Ananworanich; Mariana Gerschenson; Nipat Teeratakulpisarn; Tanate Jadwattanakul; Victor DeGruttola; Justin C McArthur; Gigi Ebenezer; Nitiya Chomchey; Pairoa Praihirunkit; Piranun Hongchookiat; Pornpen Mathajittiphun; Beau Nakamoto; Peter Hauer; Praphan Phanuphak; Nittaya Phanuphak
Journal:  J Neurovirol       Date:  2015-05-22       Impact factor: 2.643

Review 4.  HIV-related neuropathy: current perspectives.

Authors:  Sonja G Schütz; Jessica Robinson-Papp
Journal:  HIV AIDS (Auckl)       Date:  2013-09-11

5.  The Protective Effects of IGF-1 on Different Subpopulations of DRG Neurons with Neurotoxicity Induced by gp120 and Dideoxycytidine In Vitro.

Authors:  Lin Lu; Haixia Dong; Guixiang Liu; Bin Yuan; Yizhao Li; Huaxiang Liu
Journal:  Biomol Ther (Seoul)       Date:  2014-11-30       Impact factor: 4.634

Review 6.  Epidemiology of Peripheral Neuropathy: An Indian Perspective.

Authors:  Sweety Trivedi; Alak Pandit; Goutam Ganguly; Shyamal Kumar Das
Journal:  Ann Indian Acad Neurol       Date:  2017 Jul-Sep       Impact factor: 1.383

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.